Important Registration and Event Details
- Registration is $20 and includes access to the webinar recording, downloadable PDF slides, and a bonus trial evidence review and executive summary resource
- Due to the nature of digital products, no refunds will be issued after purchase
- You must opt into subscribing to Spirit Pharmacist emails during the checkout process in order to receive the link to the webinar recording. If you do not receive that email within an hour after you purchase, please reach out to admin@spiritpharmacist.com
Workshop Overview:
About 10 million Americans microdosed a psychedelic in 2025. That is roughly 4% of the U.S. adult population, and the majority are doing it for health-related reasons rather than for recreation. The numbers say the public is speaking. They are searching for something else and wondering if psychedelic microdosing is it.
At the same time, clinical research has been accumulating. The 2021 to 2026 window represents the first serious concentration of placebo-controlled human evidence on microdosing. Twelve controlled trials and two open-label studies are now available with new data on mood, cognition, ADHD, pain, sleep, and depression. Methodological debates about expectancy effects, blinding integrity, and what a true pharmacological signal looks like at sub-perceptual doses have hallmarked this era.
This webinar synthesizes the full body of controlled human evidence on psychedelic microdosing from 2021 through 2026. We will work through the results trial by trial and domain by domain, identify where the evidence is stronger, where it is preliminary, and where it is null. We will discuss what we have learned, what remains genuinely unsettled, and what is coming next in the trial pipeline.
Our formal learning objectives are to:
- Summarize the design, population, and key findings of all identified placebo-controlled microdosing trials published between 2021 and 2026
- Evaluate the strength of controlled evidence across key outcome domains, including mood, cognition, creativity, ADHD, pain, sleep, and depression
- Identify expectancy effects, blinding failure, and other methodological challenges that limit interpretation of microdosing research
- Describe the most clinically promising signals in the current data and explain what distinguishes them from null findings
- Outline registered and ongoing trials that will advance the field over the next two to four years
Webinar Disclaimer
This webinar is for information and educational purposes only. It is not meant to condone or encourage the use of illicit substances. The information presented is not medical advice and should not be taken as such. It is recommended you follow laws applicable to your jurisdiction.